CDCP1 and neoplasm: The lack of xenograft growth inhibition upon anti-CDCP1 therapy as a single-agent could result from several factors, one of which is the individual sensitivity of different tumour models; the in vitro screens were performed with cells from a stage I KRasWT tumour, whereas the xenografts were derived from a stage IV KRasmut-P53mut tumour that had not been cultured in vitro prior to implantation.